Cell affinity for bFGF immobilized heparin-containing poly(lactide-co-glycolide) scaffolds

Biomaterials

Volumn 32, Issue 13, 2011, Pages 3404-3412

  Shen, Hong ^a   Hu, Xixue ^a   Yang, Fei ^a   Bei, Jianzhong ^a   Wang, Shenguo ^a  

^a INSTITUTE OF CHEMISTRY   (China)

Author keywords

BFGF; Heparin; Immobilization; PLGA; Scaffold; Slow release

Indexed keywords

BFGF; HEPARIN; IMMOBILIZATION; PLGA; SLOW RELEASE;

BIOACTIVITY; BLENDING; CELL CULTURE; FIBROBLASTS; MOLECULAR WEIGHT; POLYSACCHARIDES; TISSUE;

SCAFFOLDS;

HEPARIN; MOLECULAR SCAFFOLD; POLYGLACTIN; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CELL ADHESION; CELL GROWTH; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG RELEASE; FIBROBLAST; IMMOBILIZED CELL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; STATIC ELECTRICITY;

3T3 CELLS; ANIMALS; CELL ADHESION; CELL PROLIFERATION; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HEPARIN; LACTIC ACID; MICE; POLYGLYCOLIC ACID; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 79951977723     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.01.037     Document Type: Article

References (42)

1. Biondi M., Ungaro F., Quaglia F., Netti P.A. Controlled drug delivery in tissue engineering. Adv Drug Delivery Rev 2008, 60:229-242.
2. Yan Y.N., Xiong Z., Hu Y.Y., Wang S.G., Zhang R.J., Zhang C. Layered manufacturing of tissue engineering scaffolds via multi-nozzle deposition. Mater Lett 2003, 57:2623-2628.
3. Ma Z.W., Gao C.Y., Gong Y.H., Shen J.C. Cartilage tissue engineering PlLA scaffold with surface immobilized collagen and basic fibroblast growth factor. Biomaterials 2005, 26:1253-1259.
4. Allen K.D., Athanasiou K.A. Scaffold and growth factor selection in temporomandibular joint disc engineering. J Dent Res 2008, 87:180-185.
5. Hu X.X., Shen H., Yang F., Bei J.Z., Wang S.G. Preparation and cell affinity of microtubular orientation-structured PLGA(70/30) blood vessel scaffold. Biomaterials 2008, 29:3128-3136.
6. Liu X.H., Won Y.J., Ma P.X. Surface modification of interconnected porous scaffolds. J Biomed Mater Res 2005, 74A:84-91.
7. Shen H., Hu X.X., Yang F., Bei J.Z., Wang S.G. Combining oxygen plasma treatment with anchorage of cationized gelatin for enhancing cell affinity of poly(lactide-co-glycolide). Biomaterials 2007, 28:4219-4230.
8. Shen H., Hu X.X., Yang F., Bei J.Z., Wang S.G. An injectable scaffold: rhBMP-2-loaded poly(lactide-co-glycolide)/hydroxyapatite composite microspheres. Acta Biomater 2010, 6:455-465.
9. Babensee J.E., Mcintire L.V., Mikos A.G. Growth factor delivery for tissue engineering. Pharm Res 2000, 17:497-504.
10. Fu X., Shen Z., Chen Y., Xie J., Guo Z., Zhang M., et al. Randomized placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns. Lancet 1998, 352:1661-1664.
11. Radomsky M.L., Thompson A.Y., Poser J.W. Potential role of fibroblast growth factor in enhancement of fracture healing. Clin Orthop Relat Res 1998, 355S:283-293.
12. Kirker-head C.A. Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Delivery Rev 2000, 43:65-92.
13. Allori A.C., Sailon A.M., Warren S.M. Biological basis of bone formation, remodeling, and repair - part I: biochemical signaling molecules. Tissue Eng Part B-Rev 2008, 14:259-273.
14. Dereka X.E., Markopoulou C.E., Vrotsos I.A. Role of growth factors on periodontal repair. Growth Factors 2006, 24:260-267.
15. Yoon D.M., Fisher J.P. Effects of exogenous IGF-1 delivery on the early expression of IGF-1 signaling molecules by alginate embedded chondrocytes. Tissue Eng Part A 2008, 14:1263-1273.
16. Li C., Vepari C., Jin H.J., Kim H.J., Kaplan D.L. Electrospun silk-BMP-2 scaffolds for bone tissue engineering. Biomaterials 2006, 27:3115-3124.
17. Liu A.C., Gotlieb A.I. Transforming growth factor-beta regulates in vitro heart valve repair by activated valve interstitial cells. Am J Pathol 2008, 173:1275-1285.
18. Farre J., Roura S., Prat-Vidal C., Soler-Botija C., Llach A., Molina C.E., et al. FGF-4 increases in vitro expansion rate of human adult bone marrow-derived mesenchymal stem cells. Growth Factors 2007, 25:71-76.
19. Saltzman W.M. Growth factor delivery in tissue engineering. MRS Bull 1996, 21:62-65.
20. Tabata Y., Takebayashi Y., Ueda T., Ikada Y. A formulation method using d, l-lactic acid oligomer for protein release with reduced initial burst. J Control Release 1993, 23:55-64.
21. Nimni M.E. Polypeptide growth factors: targeted delivery systems. Biomaterials 1997, 18:1201-1225.
22. Whang K., Tsai D.C., Nam E.K., Aitken M., Sprague S.M., Patel P.K., et al. Ectopic bone formation via rhBMP-2 delivery from porous bioabsorbable polymer scaffolds. J Biomed Mater Res 1998, 42:491-499.
23. Thula T.T., Schultz G., Tran-Son-Tay R., Batich C. Effects of EGF and bFGF on irradiated parotid glands. Ann Biomed Eng 2005, 33:685-695.
24. Wang S.G., Cai Q., Hou J.W., Bei J.Z., Zhang T., Yang J., et al. Acceleration effect of basic fibroblast growth factor on the regeneration of peripheral nerve through a 15 mm gap. J Biomed Mater Res 2003, 66A:522-531.
25. Xiong Z., Yan Y.N., Wang S.G., Zhang R.J., Zhang C. Fabrication of porous scaffolds for bone tissue engineering via low-temperature deposition. Scr Mater 2002, 46:771-776.
26. Jeon O., Rhie J.W., Kwon I.K., Kim J.H., Kim B.S., Lee S.H. In vivo bone formation following transplantation of human adipose-derived stromal cells that are not differentiated osteogenically. Tissue Eng: Part A 2008, 14:1285-1294.
27. Cowan C.M., Aghaloo T., Chou Y.F., Walder B., Zhang X.L., Soo C., et al. MicroCT evaluation of three-dimensional mineralization in response to BMP-2 doses in vitro and in critical sized rat calvarial defects. Tissue Eng 2007, 13:501-512.
28. Shen H., Hu X.X., Bei J.Z., Wang S.G. The immobilization of basic fibroblast growth factor on plasma-treated poly(lactide-co-glycolide). Biomaterials 2008, 29:2388-2399.
29. Shen H., Hu X.X., Yang F., Bei J.Z., Wang S.G. The bioactivity of rhBMP-2 immobilized poly(lactide-co-glycolide) scaffolds. Biomaterials 2009, 30:3150-3157.
30. Wan Y.Q., Tu C.F., Yang J., Bei J.Z., Wang S.G. Influences of ammonia plasma treatment on modifying depth and degradation of poly(l-lactide) scaffolds. Biomaterials 2006, 27:2699-2704.
31. Jeon O., Song S.J., Kang S.W., Putnam A.J., Kim B.S. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(l-lactic-co-glycolic acid) scaffold. Biomaterials 2007, 28:2763-2771.
32. Yoon J.J., Chung H.J., Lee H.J., Park T.G. Heparin-immobilized biodegradable scaffolds for local and sustained release of angiogenic growth factor. J Biomed Mater Res Part A 2006, 79A:934-942.
33. Zhang L., Furst E.M., Kiick K.L. Manipulation of hydrogel assembly and growth factor delivery via the use of peptide-polysaccharide interactions. J Control Release 2006, 114:130-142.
34. Spillmann D., Lindahl U. Glycosaminoglycan protein interactions - a question of specificity. Curr Opin Struct Biol 1994, 4:677-682.
35. Lin H., Zhao Y.N., Sun W.J., Chen B., Zhang J., Zhao W.X., et al. The effect of crosslinking heparin to demineralized bone matrix on mechanical strength and specific binding to human bone morphogenetic protein-2. Biomaterials 2008, 29:1189-1197.
36. Lee A.C., Yu V.M., Lowe J.B., Brenner M.J., Hunter D.A., Mackinnon S.E., et al. Controlled release of nerve growth factor enhances sciatic nerve regeneration. Exp Neurol 2003, 184:295-303.
37. Gilding D.K., Reed A.M. Biodegradable polymers for use in surgery-polyglycolic/polylactic acid homo and copolymers. Polymer 1979, 20:1459-1464.
38. Jee K.S., Park H.D., Park K.D., Kim Y.H., Shin J.W. Heparin conjugated polylactide as a blood compatible material. Biomacromolecules 2004, 5:1877-1881.
39. Shi G.X., Cai Q., Wang C.Y., Lu N., Wang S.G., Bei J.Z. Fabrication of cell scaffold of poly(l-lactic acid) and poly(l-lactic-co-glycolic acid) and biocompatibility. Polym Adv Technol 2002, 13:227-232.
40. Smith P.K., Mallia A.K., Hermanson G.T. Colorimetric method for the assay of heparin content in immobilized heparin preparations. Anal Biochem 1980, 109:466-473.
41. Clowes A.W., Karnovsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977, 265:625-626.
42. Nikitovic D., Zafiropoulos A., Tzanakakis G.N., Karamanos N.K., Tsatsakis A.M. Effects of glycosaminoglycans on cell proliferation of normal osteoblasts and human osteosarcoma cells depend on their type and fine chemical compositions. Anticancer Res 2005, 25:2851-2856.